PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study

Abstract Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish regist...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Deirdre Cronin-Fenton, Tapashi Dalvi, Naimisha Movva, Lars Pedersen, Hanh Hansen, Jon Fryzek, Elizabeth Hedgeman, Anders Mellemgaard, Torben R. Rasmussen, Norah Shire, Stephen Hamilton-Dutoit, Mette Nørgaard
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/b4c1a9ab9ce54222a8cc1b0d41e549b9
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Documents similaires